Author:
Kastritis Efstathios,Beksac Meral,Badelita Sorina Nicoleta,Katodritou Eirini,Bila Jelena,Spanoudakis Emmanouil,Seval Guldane Cengiz,Cvetkovic Zorica,Markovic Olivera,Toprak Selami Koçak,Dalampira Dimitra,Coriu Daniel,Bezirgiannidou Zoi,Pirsic Mario,Valkovic Toni,Ursuleac Iulia,Sretenovic Aleksandra,Sevastoudi Angeliki,Batinic Josip,Barbu Sinziana,Roussou Maria,Gavriatopoulou Maria,Terpos Evangelos,Dimopoulos Meletios A.
Reference24 articles.
1. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up;Dimopoulos;Hemasphere,2021
2. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial;Reeder;Leukemia,2009
3. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma;Attal;N Engl J Med,2017
4. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma;Richardson;N Engl J Med,2022
5. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma;Rosinol;Blood,2019